Abstract:Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened new avenues towards the development of novel assets to achieve durable immune control of cancer. Yet, the presence of tumor immune evasion mechanisms represents a challenge for the development of efficient treatment options. Therefore, combination therapies are taking the center of the stage in immuno-oncology. Such combination therapies should boost anti-tumor immune responses and/or target tumor immune escape mechanisms, especially those created by major players in the tumor microenvironment (TME) such as tumor-associated macrophages (TAM). Natural killer (NK) cells were recently positioned at the forefront of many immunotherapy strategies, and several new approaches are being designed to fully exploit NK cell antitumor potential. One of the most relevant NK cell-activating receptors is NKG2D, a receptor that recognizes 8 different NKG2D ligands (NKG2DL), including MICA and MICB. MICA and MICB are poorly expressed on normal cells but become upregulated on the surface of damaged, transformed or infected cells as a result of post-transcriptional or post-translational mechanisms and intracellular pathways. Their engagement of NKG2D triggers NK cell effector functions. Also, MICA/B are polymorphic and such polymorphism affects functional responses through regulation of their cell-surface expression, intracellular trafficking, shedding of soluble immunosuppressive isoforms, or the affinity of NKG2D interaction. Although immunotherapeutic approaches that target the NKG2D-NKG2DL axis are under investigation, several tumor immune escape mechanisms account for reduced cell surface expression of NKG2DL and contribute to tumor immune escape. Also, NKG2DL polymorphism determines functional NKG2D-dependent responses, thus representing an additional challenge for leveraging NKG2DL in immuno-oncology. In this review, we discuss strategies to boost MICA/B expression and/or inhibit their shedding and propose that combination strategies that target MICA/B with antibodies and strategies aimed at promoting their upregulation on tumor cells or at reprograming TAM into pro-inflammatory macrophages and remodeling of the TME, emerge as frontrunners in immuno-oncology because they may unleash the antitumor effector functions of NK cells and cytotoxic CD8 T cells (CTL). Pursuing several of these pipelines might lead to innovative modalities of immunotherapy for the treatment of a wide range of cancer patients.

Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

Immune Checkpoint Molecules in Natural Killer Cells As Potential Targets for Cancer Immunotherapy.

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy

Immune Evasion and Therapeutic Opportunities Based on Natural Killer Cells.

Natural killer cells in cancer immunotherapy

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment

The Rise of NK Cell Checkpoints As Promising Therapeutic Targets in Cancer Immunotherapy

Role of NKG2D and Its Ligands in Cancer Immunotherapy.

NK Cell-Based Immune Checkpoint Inhibition

Tumor Immune Checkpoints and Their Associated Inhibitors

Leveraging NKG2D Ligands in Immuno-Oncology

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications

Natural killer group 2D receptor and its ligands in cancer immune escape

NK Cell Dysfunction and Checkpoint Immunotherapy

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells